SCHEMBL20021919

SCHEMBL20021919

CCCOc1ccc(C(=O)OC)cc1-c1ccc(F)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL9 O00512 7/20 0.54
CTNNB1 P35222 7/20 0.54
SYK P43405 1/20 0.48
PTGS1 P23219 1/20 0.48
SLC6A4 P31645 1/20 0.45
SLC6A3 Q01959 1/20 0.45
PDE4D Q08499 1/20 0.45
PPARG P37231 1/20 0.44
NLRP3 Q96P20 1/20 0.44
KDM4E B2RXH2 1/20 0.43
PTPN7 P35236 1/20 0.43
MAPT P10636 2/20 0.43
ALDH1A1 P00352 1/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
HPSE Q9Y251 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18165180 0.88 RARB (0.53) BCL9CTNNB1SYKPTGS1KDM4E
SCHEMBL20021935 0.88 BCL9 (0.55) BCL9CTNNB1PDE4DNLRP3BRD4
SCHEMBL20021933 0.87 BCL9 (0.53) BCL9CTNNB1SYKKMT2AHPSE
SCHEMBL20021929 0.86 BCL9 (0.55) BCL9CTNNB1SYKPTGS1PDE4D
SCHEMBL18152365 0.82 SYK (0.49) BCL9CTNNB1SYKPTGS1SLC6A4
SCHEMBL4601631 0.81 L3MBTL1 (0.53) KDM4EMAPTALDH1A1MEN1MAPK1
SCHEMBL18152400 0.81 BCL9 (0.46) BCL9CTNNB1SYKPTGS1PTPN7
SCHEMBL15295180 0.81 PDE4D (0.53) PDE4DNLRP3KDM4EMAPTMAPK1
SCHEMBL4426964 0.80 EGFR (0.52) BCL9CTNNB1PTGS1SLC6A4SLC6A3
SCHEMBL16056073 0.79 EGFR (0.51) PTGS1SLC6A4SLC6A3KDM4EPTPN7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180092866-A1 SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY 2018-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180092866-A1 SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS BCL9, BCL9L, BCL3 BCL9 1/4885CTNNB1 4/4885SYK 2252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.